Ras oncogenes: split personalities

Cited by (1,000)

Items 201–300 of 1,000

1. Absence of Neurofibromin Induces an Oncogenic Metabolic Switch via Mitochondrial ERK-Mediated Phosphorylation of the Chaperone TRAP1
   Ionica Masgras, Francesco Ciscato, Anna Maria Brunati, Elena V. Tibaldi, Stefano Indraccolo, Matteo Curtarello, Federica Chiara, Giuseppe Cannino, Elena Papaleo, Matteo Lambrughi et al. · 2017 · Cell Reports
2. Structural and functional characterization of a DARPin which inhibits Ras nucleotide exchange
   Sandrine Guillard, Paulina Kolasinska-Zwierz, J.E. Debreczeni, Jason Breed, Jing Zhang, Nicolas Béry, Rose Marwood, Jonathan Tart, R. Overman, Paweł Stocki et al. · 2017 · Nature Communications
3. Targeting Ras-RAF-ERK and its Interactive Pathways as a Novel Therapy for Malignant Gliomas
   Hui‐Wen Lo · 2010 · Current Cancer Drug Targets
4. Activation of KRAS promotes the mesenchymal features of basal-type breast cancer
   Rae-Kwon Kim, Yongjoon Suh, Ki-Chun Yoo, Yan‐Hong Cui, Hyeonmi Kim, Min-Jung Kim, In Gyu Kim, Su-Jae Lee · 2015 · Experimental & Molecular Medicine
5. KRAS Protein Stability Is Regulated through SMURF2: UBCH5 Complex-Mediated β-TrCP1 Degradation
   Shukla, Shirish, Allam, Uday Sankar, Ahsan, Aarif, Chen, Guoan, Krishnamurthy, Pranathi Meda, Marsh, Katherine, Rumschlag, Matthew, Shankar, Sunita, Whitehead, Christopher, Schipper, Matthew et al. · 2014 · Neoplasia
6. PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1α
   Iris Eke, Ulrike Koch, Stephanie Hehlgans, Veit Sandfort, Fabio Stanchi, Daniel Zips, Michael A. Baumann, Anna Shevchenko, Christian P. Pilarsky, Michael Haase et al. · 2010 · Journal of Clinical Investigation
7. MicroRNAs mediated regulation of MAPK signaling pathways in chronic myeloid leukemia
   Chiranjib Chakraborty, Ashish Ranjan Sharma, Bidhan Chandra Patra, Manojit Bhattacharya, Garima Sharma, Sang‐Soo Lee · 2016 · Oncotarget
8. Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
   Jieqiong Wang, Kewen Hu, Jiawei Guo, Feixiong Cheng, Jing Lv, Wenhao Jiang, Weiqiang Lü, Jinsong Liu, Xiufeng Pang, Mingyao Liu · 2016 · Nature Communications
9. Metabolic Plasticity of Tumor Cell Mitochondria
   Giuseppe Cannino, Francesco Ciscato, Ionica Masgras, Carlos Sànchez‐Martìn, Andrea Rasola · 2018 · Frontiers in Oncology
10. Pancreatic cancer: Circulating Tumor Cells and Primary Tumors show Heterogeneous KRAS Mutations
    Birte Kulemann, Stephanie Rösch, Sindy Seifert, Sylvia Timme, Peter Bronsert, Gabriel J. Seifert, Verena Martini, Jasmina Kuvendjiska, Torben Glatz, Saskia Hussung et al. · 2017 · Scientific Reports
11. NF-κB as a target for pancreatic cancer therapy
    Carmine Carbone, Davide Melisi · 2012 · Expert Opinion on Therapeutic Targets
12. RNA G-Quadruplexes in Kirsten Ras ( KRAS ) Oncogene as Targets for Small Molecules Inhibiting Translation
    Giulia Miglietta, Susanna Cogoi, Jessica Marinello, Giovanni Capranico, Alexander S. Tikhomirov, Andrey Egorovich Shchekotikhin, Luigi Emilio Xodo · 2017 · Journal of Medicinal Chemistry
13. Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis
    Chengqian Yin, Bo Zhu, Ting Zhang, Tongzheng Liu, Shuyang Chen, Yu Liu, Xin Li, Xiao Miao, Shanshan Li, Xia Mi et al. · 2019 · Cell
14. SAG/RBX2/ROC2 E3 Ubiquitin Ligase Is Essential for Vascular and Neural Development by Targeting NF1 for Degradation
    Mingjia Tan, Yongchao Zhao, Sun-Jung Kim, Margaret Liu, Lijun Jia, Thomas L. Saunders, Yuan Zhu, Yi Sun · 2011 · Developmental Cell
15. A MEK Inhibitor Abrogates Myeloproliferative Disease in Kras Mutant Mice
    Natalya Lyubynska, Matthew F. Gorman, Jennifer Lauchle, Wan Xing Hong, Jon Akutagawa, Kevin Shannon, Benjamin S. Braun · 2011 · Science Translational Medicine
16. Helicobacter pylori–induced RASAL2 Through Activation of Nuclear Factor-κB Promotes Gastric Tumorigenesis via β-catenin Signaling Axis
    Long‐Long Cao, Shoumin Zhu, Heng Lu, Mohammed Soutto, Nadeem Sidiq Bhat, Zheng Chen, Dunfa Peng, Jian‐Xian Lin, Jun Kun Lu, Ping Li et al. · 2022 · Gastroenterology
17. Membrane-associated Ras dimers are isoform-specific: K-Ras dimers differ from H-Ras dimers
    Hyunbum Jang, Serena Muratcioğlu, Attila Gürsoy, Özlem Keskin, Ruth Nussinov · 2016 · Biochemical Journal
18. The Distinct Conformational Dynamics of K-Ras and H-Ras A59G
    Suryani Lukman, Barry J. Grant, Alemayehu Abebe Gorfe, Guy H. Grant, James Andrew McCammon · 2010 · PLoS Computational Biology
19. Thioredoxin (Trx): A redox target and modulator of cellular senescence and aging-related diseases
    Bowen Yang, Yumeng Lin, Yibo Huang, Ying-Qiang Shen, Qianming Chen · 2024 · Redox Biology
20. Decreased Expression of the RAS-GTPase Activating Protein RASAL1 Is Associated With Colorectal Tumor Progression
    Miki Ohta, Motoko Seto, Hideaki Ijichi, Koji Miyabayashi, Yotaro Kudo, Dai Mohri, Yoshinari Asaoka, Motohisa Tada, Yasuo Tanaka, Tsuneo Ikenoue et al. · 2008 · Gastroenterology
21. Identification of Y-Box Binding Protein 1 As a Core Regulator of MEK/ERK Pathway-Dependent Gene Signatures in Colorectal Cancer Cells
    Karsten Jürchott, Ralf‐Jürgen Kuban, Till Krech, Nils Blüthgen, Ulrike Stein, Wolfgang Walther, Christian Friese, Szymon M. Kiełbasa, Ute Ungethüm, Per Lund et al. · 2010 · PLoS Genetics
22. A PDE6δ‐KRas Inhibitor Chemotype with up to Seven H‐Bonds and Picomolar Affinity that Prevents Efficient Inhibitor Release by Arl2
    Pablo Martín‐Gago, Eyad K. Fansa, Christian H. Klein, Sandip Murarka, Petra Janning, Marc Schürmann, Malte Metz, Shehab Ismail, Carsten Schultz‐Fademrecht, Matthias Baumann et al. · 2017 · Angewandte Chemie International Edition
23. ERK and PDE4 cooperate to induce RAF isoform switching in melanoma
    Amélie Marquette, Jocelyne André, Martine Bagot, Armand Bensussan, Nicolas Dumaz · 2011 · Nature Structural & Molecular Biology
24. Aggregation and Prion-Like Properties of Misfolded Tumor Suppressors: Is Cancer a Prion Disease?
    Danielly C. Ferraz da Costa, Guilherme A. P. de Oliveira, Elio A. Cino, Iaci N. Soares, Luciana Pereira Rangel, Jerson Lima Silva · 2016 · Cold Spring Harbor Perspectives in Biology
25. DNA replication stress: oncogenes in the spotlight
    Luiza M. F. Primo, Leonardo K. Teixeira · 2019 · Genetics and Molecular Biology
26. Targeting KRAS in Cancer: Promising Therapeutic Strategies
    Lisa Maria Mustachio, Anca Chelariu-Raicu, Lóránt Székvölgyi, Jason Roszik · 2021 · Cancers
27. Reconstructing targetable pathways in lung cancer by integrating diverse omics data
    O. Alejandro Balbin, John R. Prensner, Anirban Sahu, Anastasia K. Yocum, Sunita Shankar, Rohit Malik, Damian Fermin, Saravana Mohan Dhanasekaran, Benjamin C. Chandler, Dafydd G. Thomas et al. · 2013 · Nature Communications
28. RSK phosphorylates SOS1 creating 14-3-3-docking sites and negatively regulating MAPK activation
    Madhurima Saha, Audrey Carriere, Mujeeburahiman Cheerathodi, Xiaocui Zhang, Geneviève Lavoie, Augustus John Rush, Philippe P. Roux, Bryan A. Ballif · 2012 · Biochemical Journal
29. A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors
    Lee S. Rosen, Patricia Mucci LoRusso, Wen Wee Ma, Jonathan Wade Goldman, Amy M. Weise, Alexander Dimitrios Colevas, Alex A. Adjei, Salim Yazji, Angela Shen, Stuart H. Johnston et al. · 2016 · Investigational New Drugs
30. Integrated RAS signaling defined by parallel NMR detection of effectors and regulators
    Smith, Matthew J, Ikura, Mitsuhiko · 2014 · Nature Chemical Biology
31. Atypical BRAF and NRAS Mutations in Mucosal Melanoma
    Nicolas Dumaz, Fanélie Jouenne, Julie Delyon, Samia Mourah, Armand Bensussan, Célèste Lebbé · 2019 · Cancers
32. Rational design of allosteric modulators: Challenges and successes
    Alexios Chatzigoulas, Zoe Cournia · 2021 · Wiley Interdisciplinary Reviews Computational Molecular Science
33. Introduction to Cancer Biology
    Momna V. Hejmadi · 2010
34. STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability
    Tuoping Luo, Kristina Masson, Jacob D. Jaffe, Whitney Silkworth, Nathan T. Ross, Christina Scherer, Claudia Scholl, Stefan Fröhling, Steven A. Carr, Andrew M. Stern et al. · 2012 · Proceedings of the National Academy of Sciences
35. SIRT6 regulates Ras-related protein R-Ras2 by lysine defatty-acylation
    Xiaoyu Zhang, Nicole A. Spiegelman, Ornella D. Nelson, Hui Jing, Hening Lin · 2017 · eLife
36. Ribosome profiling analysis identified a KRAS-interacting microprotein that represses oncogenic signaling in hepatocellular carcinoma cells
    Wenli Xu, Bing Deng, Penghui Lin, Chang Liu, Bin Li, Qiao-Juan Huang, Hui Zhou, Jianhua Yang, Liang‐Hu Qu · 2019 · Science China Life Sciences
37. Tumor suppression by p53: making cells senescent.
    Yingjuan Qian, Xinbin Chen · 2010 · PubMed
38. DEPTOR at the Nexus of Cancer, Metabolism, and Immunity
    Alexandre Caron, David Michael Briscoe, Denis Richard, Mathieu Laplante · 2018 · Physiological Reviews
39. Canonical RTK-Ras-ERK signaling and related alternative pathways
    Meera V. Sundaram · 2013 · WormBook
40. Raf activation by Ras and promotion of cellular metastasis require phosphorylation of prohibitin in the raft domain of the plasma membrane
    C-F Chiu, M Ho, J-M Peng, Hung Sw, W-H Lee, C-M Liang, S-M Liang · 2012 · Oncogene
41. Targeting β‐catenin in hepatocellular cancers induced by coexpression of mutant β‐catenin and K‐Ras in mice
    Junyan Tao, Rong Zhang, Sucha Singh, Minakshi Poddar, Emily Xu, Michael Oertel, Xin Chen, Shanthi Ganesh, Marc T. Abrams, Satdarshan P. Monga · 2016 · Hepatology
42. Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression
    Dai Mohri, Yoshinari Asaoka, Hideaki Ijichi, Koji Miyabayashi, Yotaro Kudo, Motoko Seto, Miki Ohta, Motohisa Tada, Yasuo Tanaka, Tsuneo Ikenoue et al. · 2011 · Journal of Gastroenterology
43. Ras1CA overexpression in the posterior silk gland improves silk yield
    Li Ma, Hanfu Xu, Jinqi Zhu, Sanyuan Ma, Yan Liu, Rong‐Jing Jiang, Qingyou Xia, Sheng Li · 2011 · Cell Research
44. Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival
    Torsten Steinbrunn, Thorsten Stühmer, Stefan Gattenlöhner, Andreas Rosenwald, Anja Mottok, Christian Unzicker, Hermann Einsele, Manik Chatterjee, Ralf Christian Bargou · 2010 · Blood
45. MELK Promotes Melanoma Growth by Stimulating the NF-κB Pathway
    Radoslav Janoštiak, Navin Rauniyar, TuKiet T. Lam, Jianhong Ou, Lihua Julie Zhu, Michael R. Green, Narendra Wajapeyee · 2017 · Cell Reports
46. The role of autophagy in cancer: from molecular mechanism to therapeutic window
    Pooya Jalali, Arvin Shahmoradi, Amir Samii, Radman Mazloomnejad, Mohammad Reza Hatamnejad, Anwaar Saeed, Afshin Namdar, Zahra Salehi · 2025 · Frontiers in Immunology
47. Crystal structures of the state 1 conformations of the GTP‐bound H‐Ras protein and its oncogenic G12V and Q61L mutants
    Shin Muraoka, Fumi Shima, Mitsugu Araki, Tomoko Inoue, Akiko Yoshimoto, Yuichi Ijiri, Nobuaki Seki, Atsuo Tamura, Takashi Kumasaka, Masaki Yamamoto et al. · 2012 · FEBS Letters
48. Novel therapeutic agents for osteosarcoma
    Kathleen O’Day, Richard Greg Gorlick · 2009 · Expert Review of Anticancer Therapy
49. On the intrinsic inevitability of cancer: From foetal to fatal attraction
    Sui Huang · 2011 · Seminars in Cancer Biology
50. Oncogenes create a unique landscape of fragile sites
    Karin Miron, Tamar Golan‐Lev, Raz Dvir-Szternfeld, Eyal Ben‐David, Batsheva Kerem · 2015 · Nature Communications
51. Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer
    Sander Mertens, Maarten A. Huismans, Carla S. Veríssimo, Bas Ponsioen, René Overmeer, Natalie Proost, Olaf van Tellingen, Marieke van de Ven, Harry Begthel, Sylvia F. Boj et al. · 2023 · Cell Reports
52. Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras
    Jin Xu, Christian Hedberg, Frank J. Dekker, Qing Li, Kevin M. Haigis, Eugene Hwang, Herbert Waldmann, Kevin Shannon · 2011 · Blood
53. Cucurbitacin IIa: a novel class of anti-cancer drug inducing non-reversible actin aggregation and inhibiting survivin independent of JAK2/STAT3 phosphorylation
    Christi Boykin, Guangyong Zhang, Y-H Chen, R-W Zhang, X-E Fan, W-M Yang, Qun Lu · 2011 · British Journal of Cancer
54. Real-time single-molecule co-immunoprecipitation analyses reveal cancer-specific Ras signalling dynamics
    Hong-Won Lee, Taeyoon Kyung, Janghyun Yoo, Tackhoon Kim, Chaeuk Chung, Ji Young Ryu, Hanki Lee, Kihyun Park, Sangkyu Lee, Walton D. Jones et al. · 2013 · Nature Communications
55. High-affinity interaction of the K-Ras4B hypervariable region with the RAS active site
    Chavan, Tanmay S., Jang, Hyunbum, Khavrutskii, Lyuba, Abraham, Sherwin J., Banerjee, Avik, Freed, Benjamin C., Johannessen, Liv, Tarasov, Sergey G., Gaponenko, Vadim, Nussinov, Ruth et al. · 2015 · Biophysical Journal
56. DARPA's Big Mechanism program
    Paul R. Cohen · 2015 · Physical Biology
57. RAS in pancreatic cancer
    Simone Lanfredini, Asmita Thapa, Eric E. O’Neill · 2019 · Biochemical Society Transactions
58. Autophagy modulators for the treatment of oral and esophageal squamous cell carcinomas
    Tuhina Khan, Nicola Relitti, Margherita Brindisi, Stefania Magnano, Daniela M. Zisterer, Sandra Gemma, Stefania Butini, Giuseppe Campiani · 2019 · Medicinal Research Reviews
59. RASAL2 promotes tumor progression through LATS2/YAP1 axis of hippo signaling pathway in colorectal cancer
    Yi Pan, JOANNA H.M. TONG, Raymond Wai Ming Lung, Wei Kang, Johnny S. H. Kwan, Wing Po Chak, Ka Yee Tin, Lau Ying Chung, Feng Wu, Simon S.M. Ng et al. · 2018 · Molecular Cancer
60. The Ras Superfamily of Small GTPases in Non-neoplastic Cerebral Diseases
    Liang Qu, Chao Pan, Shiming He, Bing Lang, Guo-Dong Gao, Xuelian Wang, Yuan Wang · 2019 · Frontiers in Molecular Neuroscience
61. Regulation and signaling of human bombesin receptors and their biological effects
    Horst Christian Weber · 2009 · Current Opinion in Endocrinology Diabetes and Obesity
62. CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
    Sara Costa-Cabral, Rachel Brough, Asha Konde, Marieke Aarts, James Campbell, Eliana Marinari, Jenna L. Riffell, Alberto Bardelli, Christopher J. Torrance, Christopher J. Lord et al. · 2016 · PLoS ONE
63. Lack of Transcription Triggers H3K27me3 Accumulation in the Gene Body
    Masaki Hosogane, Ryo Funayama, Matsuyuki Shirota, Keiko Nakayama · 2016 · Cell Reports
64. Oncoapoptotic signaling and deregulated target genes in cancers: Special reference to oral cancer
    Zakir Khan, Prakash Singh Bisen · 2013 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
65. Methylation of RASSF1A, RASSF2A , and HIN-1 Is Associated with Poor Outcome after Radiotherapy, but not Surgery, in Oral Squamous Cell Carcinoma
    Kuo-Hao Huang, Shiang‐Fu Huang, I‐How Chen, Chun‐Ta Liao, Hung‐Ming Wang, Ling‐Ling Hsieh · 2009 · Clinical Cancer Research
66. Erythropoietin-Induced Activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK Pathways Promotes Malignant Cell Behavior in a Modified Breast Cancer Cell Line
    Zhanzhong Shi, Vivien M. Hodges, Elaine A. Dunlop, Melanie J. Percy, Alexander Peter Maxwell, Mohamed El‐Tanani, Terry R.J. Lappin · 2010 · Molecular Cancer Research
67. Drugging All RAS Isoforms With One Pocket
    Dirk Kessler, Andreas Bergner, Jark Böttcher, Gerhard Fischer, Sandra Döbel, Melanie Hinkel, Barbara Müllauer, Alexander Weiss-Puxbaum, Darryl B. McConnell · 2020 · Future Medicinal Chemistry
68. The Ras‐ERK pathway: Understanding site‐specific signaling provides hope of new anti‐tumor therapies
    Fernando Calvo, Lorena Agudo‐Ibáñez, Piero Crespo · 2010 · BioEssays
69. The higher level of complexity of K‐Ras4B activation at the membrane
    Hyunbum Jang, Avik Banerjee, Tanmay Chavan, Shaoyong Lu, Jian Zhang, Vadim Gaponenko, Ruth Nussinov · 2015 · The FASEB Journal
70. JNK signaling is converted from anti- to pro-tumor pathway by Ras-mediated switch of Warts activity
    Enomoto, Masato, Kizawa, Daisuke, Ohsawa, Shizue, Igaki, Tatsushi · 2015 · Developmental Biology
71. Antitumor Drugs and Their Targets
    Zlatko Dembić · 2020 · Molecules
72. Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33
    Ninel Azoitei, Christopher M. Hoffmann, Jana M. Ellegast, Claudia R. Ball, Kerstin Obermayer, Ulrike Gößele, Britta Koch, Katrin Faber, Felicitas Genze, Mark G. Schrader et al. · 2012 · The Journal of Experimental Medicine
73. MALAT1 silencing suppresses prostate cancer progression by upregulating miR-1 and downregulating KRAS
    Junkai Chang, Weibo Xu, Xinyi Du, Junqing Hou · 2018 · OncoTargets and Therapy
74. Drugging K-RasG12C through covalent inhibitors: Mission possible?
    Ni, Duan, Li, Xinyi, He, Xinheng, Zhang, Hao, Zhang, Jian, Lu, Shaoyong · 2019 · Pharmacology & Therapeutics
75. Commonality but Diversity in Cancer Gene Fusions
    Rabbitts, Terence H. · 2009 · Cell
76. KRAS mutations drive adenomatoid odontogenic tumor and are independent of clinicopathological features
    Bruna Pizziolo Coura, Vanessa Fátima Bernardes, Sílvia Ferreira de Sousa, Josiane Alves França, Núbia Braga Pereira, Hélder Antônio Rebelo Pontes, Aline Carvalho Batista, Danyel Elias da Cruz Pérez, Ricardo Luiz Cavalcanti de Albuquerque Júnior, Lélia Batista de Souza et al. · 2019 · Modern Pathology
77. Molecules linked to Ras signaling as therapeutic targets in cardiac pathologies
    Manuel Ramos-Kuri, Sri Harika Meka, Fabio Salamanca‐Buentello, Roger J. Hajjar, Larissa Lipskaia, Elie R. Chemaly · 2021 · Biological Research
78. Compartmentalized signalling: Ras proteins and signalling nanoclusters
    Jasminka Omerović, Ian A. Prior · 2009 · FEBS Journal
79. MEK targeting in N-RAS mutated metastatic melanoma
    Jaykumar Ranchodbhai Thumar, David Shahbazian, Saadia A. Aziz, Lucia B. Jilaveanu, Harriet M. Kluger · 2014 · Molecular Cancer
80. Preoperative detection of RAS mutation may guide extent of thyroidectomy
    Snehal G. Patel, Sally E. Carty, Kelly L. McCoy, N. Paul Ohori, Shane O. LeBeau, Raja R. Seethala, Marina N. Nikiforova, Yuri E. Nikiforov, Linwah Yip · 2016 · Surgery
81. Suppression of MicroRNA 200 Family Expression by Oncogenic KRAS Activation Promotes Cell Survival and Epithelial-Mesenchymal Transition in KRAS-Driven Cancer
    Xiaomin Zhong, Lan Zheng, Jianfeng Shen, Dongmei Zhang, Minmin Xiong, Youyou Zhang, Xinhong He, Janos Laszlo Tanyi, Feng Yang, Kathleen T. Montone et al. · 2016 · Molecular and Cellular Biology
82. Bladder Cancer in the Genomic Era
    Charles Chuanhai Guo, Bogdan A. Czerniak · 2019 · Archives of Pathology & Laboratory Medicine
83. The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?
    Yuko Oya, Kazuyoshi Imaizumi, Tetsuya Mitsudomi · 2024 · Lung Cancer
84. Xmrk, Kras and Myc Transgenic Zebrafish Liver Cancer Models Share Molecular Signatures with Subsets of Human Hepatocellular Carcinoma
    Weiling Zheng, Zhen Li, Anh Tuan Nguyen, Caixia Li, Alexander Emelyanov, Zhiyuan Gong · 2014 · PLoS ONE
85. Ground-glass nodules of the lung in never-smokers and smokers: clinical and genetic insights
    Yoshihisa Kobayashi, Chiara Ambrogio, Tetsuya Mitsudomi · 2018 · Translational Lung Cancer Research
86. Regulation of Ras Exchange Factors and Cellular Localization of Ras Activation by Lipid Messengers in T Cells
    Jesse E. Jun, Ignacio Rubio, Jeroen P. Roose · 2013 · Frontiers in Immunology
87. The RalB Small GTPase Mediates Formation of Invadopodia through a GTPase-Activating Protein-Independent Function of the RalBP1/RLIP76 Effector
    Neel, Nicole F., Rossman, Kent L., Martin, Timothy D., Hayes, Tikvah K., Yeh, Jen Jen, Der, Channing J. · 2012 · Molecular and Cellular Biology
88. Cdk2: a key regulator of the senescence control function of Myc
    Per Hydbring, Lars‐Gunnar Larsson · 2010 · Aging
89. PI3K: A Crucial Piece in the RAS Signaling Puzzle
    Agata Adelajda Krygowska, Esther Castellano · 2017 · Cold Spring Harbor Perspectives in Medicine
90. Small GTPases: Structure, biological function and its interaction with nanoparticles
    Siyang Song, Wenshu Cong, Shurong Zhou, Yujie Shi, Wenbing Dai, Hua Zhang, Xueqing Wang, Bing He, Qiang Zhang · 2018 · Asian Journal of Pharmaceutical Sciences
91. Evolution of the Ras-like small GTPases and their regulators
    Teunis J. P. van Dam, Johannes L. Bos, ‎Berend Snel · 2011 · Small GTPases
92. Noonan syndrome gain-of-function mutations inNRAScause zebrafish gastrulation defects
    Vincent Runtuwene, Mark van Eekelen, John Overvoorde, Holger Rehmann, Helger G. Yntema, Willy M. Nillesen, Arie van Haeringen, Ineke van der Burgt, Boudewijn M.T. Burgering, Jeroen den Hertog · 2011 · Disease Models & Mechanisms
93. Oncogenic KRAS signaling and YAP1/β-catenin: Similar cell cycle control in tumor initiation
    Ruth Nussinov, Chung‐Jung Tsai, Hyunbum Jang, Tamás Korcsmáros, Péter Csermely · 2016 · Seminars in Cell and Developmental Biology
94. The RAS-Effector Interface: Isoform-Specific Differences in the Effector Binding Regions
    Hossein Nakhaeizadeh, Ehsan Amin, Saeideh Nakhaei‐Rad, Radovan Dvorský, Mohammad Reza Ahmadian · 2016 · PLoS ONE
95. Signaling pathways in intestinal homeostasis and colorectal cancer: KRAS at centre stage
    Camille Ternet, Christina Kiel · 2021 · Cell Communication and Signaling
96. Binding hotspots on K-ras: Consensus ligand binding sites and other reactive regions from probe-based molecular dynamics analysis
    Priyanka Prakash, John F. Hancock, Alemayehu Abebe Gorfe · 2015 · Proteins Structure Function and Bioinformatics
97. Identification and Characterization of a Leucine-Rich Repeat Kinase 2 (LRRK2) Consensus Phosphorylation Motif
    Pooja Pungaliya, Yuchen Bai, Kerri Lipinski, Vasanti S. Anand, Saurabh Sen, Eugene L. Brown, Brian Bates, Peter H. Reinhart, Andrew B. West, Warren D. Hirst et al. · 2010 · PLoS ONE
98. Menin determines K-RAS proliferative outputs in endocrine cells
    Chester E. Chamberlain, David W. Scheel, Kathleen McGlynn, Hail Kim, Takeshi Miyatsuka, Juehu Wang, Vinh Q Nguyen, Shuhong Zhao, Anastasia Mavropoulos, Aswin Abraham et al. · 2014 · Journal of Clinical Investigation
99. Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
    James Cregg, Kristof Pota, Aidan C.A. Tomlinson, Jason K. Yano, Abby Marquez, Yang Liu, Christopher J. Schulze, Kyle J. Seamon, Matthew T. Holderfield, Xing Wei et al. · 2025 · Journal of Medicinal Chemistry
100. The role of G-domain orientation and nucleotide state on the Ras isoform-specific membrane interaction
     Shobhna Kapoor, Katrin Weise, Mirko Erlkamp, Gemma Triola, Herbert Waldmann, Roland Winter · 2012 · European Biophysics Journal